SCHEMBL23934285

SCHEMBL23934285

CN1C(=O)c2cc(NC(=O)c3ccccc3)cc(N)c2C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.48
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
CASP3 P42574 2/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.45
DRD2 P14416 1/20 0.45
MMP14 P50281 1/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.44
HDAC3 O15379 1/20 0.43
MAPK1 P28482 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27099939 0.90 POLB (0.50) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL27099938 0.89 KMT2A (0.49) MEN1KMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL23934281 0.87 MEN1 (0.53) ACE2MEN1KMT2ACASP3HTT
SCHEMBL27100057 0.87 CA12 (0.49) MEN1KMT2ACASP3NPC1RAB9A
SCHEMBL27099941 0.85 ALDH1A1 (0.41) MEN1KMT2AMAPTKDM4EDRD2
SCHEMBL23934284 0.84 MAPT (0.53) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL27099936 0.83 KMT2A (0.52) MEN1KMT2ACASP3HTTNPC1
SCHEMBL27100055 0.83 ALOX15 (0.47) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL23934221 0.80 CASP3 (0.60) ACE2MEN1KMT2ACASP3NPC1
SCHEMBL27100046 0.79 ALOX5 (0.49) MEN1KMT2ACASP3SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 ACE2 3970/4885MEN1 2490/4885KMT2A 2003/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 ACE2 3970/4885MEN1 2490/4885KMT2A 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.